M&A Report: The European Life Sciences Industry 2018

We are pleased to present to you the latest Carlsquare M&A Report: The European Life Sciences Industry 2018.

Traditionally the Life Sciences industry is influenced by political decisions. The Medical Device Regulation (MDR) and the In-Vitro Diagnostics Regulation (IVDR) by the European Commission have already started to show consequences. The recent US congressional elections and the tax reform implemented by President Trump are expected to show effects in the European M&A market in the coming months.

Overall the Life Sciences industry remained stable compared to previous years. Of the 850 publicly announced deals most were in the provider segment, underlining the trend of provider consolidation and transformation. The deal volume of the pharma segment has been declining, but trends like the reshaping of the global pharma distribution and specialty pharma becoming more relevant, are expected to impact deal numbers in the years ahead.

With locations in Berlin, Hamburg, Munich, London and Stockholm Carlsquare has been advising successful companies in challenging market environments on acquisitions and divestments for more than 15 years. We were able to close more than 20 transactions in the Life Sciences industry. Furthermore, we are cooperating with 56 partner companies comprising more than 600 professionals in 48 countries as part of Globalscope.

If you are planning a transaction or are interested in exchanging information on the Life Sciences market, we look forward to hearing from you. Please contact us at any time.

Contact Caroline Liechtenstein for the complete study